Oral JAK inhibitors show promising potential as a therapeutic option for refractory rosacea. However, given the small sample size and single-arm design, these findings are exploratory. Large-scale randomized controlled trials are urgently needed to validate these findings and guide stratified treatment.
Peng et al. (Sun,) studied this question.